Fluvoxamine reduces COVID-19 risk: real-time meta-analysis of 21 studies (Version 39)

Covid Analysis, Nov 2026

Fluvoxamine for COVID-19

30th treatment shown to reduce risk in November 2021, now with p = 0.00014 from 21 studies, recognized in 2 countries.

No treatment is 100% effective.
Protocols combine treatments.

Significantly lower risk is seen for mortality, hospitalization, progression, recovery, and cases. 14 studies from 14 independent teams in 8 countries show significant benefit.
Meta-analysis using the most serious outcome reported shows 39% [22‑53%] lower risk. Results are similar for Randomized Controlled Trials.
Results are very robust—in worst case exclusion sensitivity analysis 12 of 21 studies must be excluded before statistical significance is lost.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
9 other meta-analyses show significant improvements with fluvoxamine for mortality1-3, hospitalization1,4-8, progression2,8, and severity9.
9 meta-analyses show significant improvements with fluvoxamine for mortality1-3, hospitalization1,4-8, progression2,8, and severity9.
Covid Analysis et al., Nov 2026, preprint, 1 author.